BioCryst Pharmaceuticals
Stock Forecast, Prediction & Price Target
BioCryst Pharmaceuticals Financial Estimates
BioCryst Pharmaceuticals Revenue Estimates
BioCryst Pharmaceuticals EBITDA Estimates
BioCryst Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $157.17M N/A | $270.82M 72.31% | $331.41M 22.37% | Avg: $486.15M Low: $470.88M High: $503.44M avg. 46.69% | Avg: $580.10M Low: $539.47M High: $601.55M avg. 19.32% | Avg: $684.79M Low: $636.83M High: $710.11M avg. 18.04% | Avg: $783.35M Low: $728.49M High: $812.32M avg. 14.39% |
Net Income
% change YoY
| $-184.06M N/A | $-247.11M -34.25% | $-226.53M 8.32% | Avg: $-73.96M Low: $-158.37M High: $-15.37M avg. 67.35% | Avg: $55.39M Low: $19.21M High: $82.64M avg. 174.90% | Avg: $136.94M Low: $124.47M High: $143.52M avg. 147.18% | Avg: $186.91M Low: $169.89M High: $195.89M avg. 36.49% |
EBITDA
% change YoY
| $-177.65M N/A | $-143.30M 19.33% | $-116.33M 18.82% | Avg: $-373.08M Low: $-386.35M High: $-361.36M avg. -220.69% | Avg: $-445.18M Low: $-461.64M High: $-414.00M avg. -19.32% | Avg: $-525.52M Low: $-544.95M High: $-488.72M avg. -18.04% | Avg: $-601.15M Low: $-623.39M High: $-559.05M avg. -14.39% |
EPS
% change YoY
| -$1.03 N/A | -$1.33 -29.12% | -$1.18 11.27% | Avg: -$0.4 Low: -$0.82 High: -$0.08 avg. 66.09% | Avg: $0.26 Low: $0.1 High: $0.43 avg. 164.36% | Avg: $0.71 Low: $0.65 High: $0.75 avg. 176.69% | Avg: $0.97 Low: $0.88 High: $1.02 avg. 36.49% |
Operating Expenses
% change YoY
| $327.62M N/A | $412.66M 25.95% | $430.46M 4.31% | Avg: $638.18M Low: $618.15M High: $660.88M avg. 48.25% | Avg: $761.51M Low: $708.18M High: $789.68M avg. 19.32% | Avg: $898.94M Low: $835.99M High: $932.19M avg. 18.04% | Avg: $1.02B Low: $956.31M High: $1.06B avg. 14.39% |
FAQ
What is BioCryst Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 106.48% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -158.37M, average is -73.96M and high is -15.37M.
What is BioCryst Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 24.61% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $470.88M, average is $486.15M and high is $503.44M.
What is BioCryst Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 110.91% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$0.82, average is -$0.4 and high is $-0.08.
What is the best performing analyst?
In the last twelve months analysts have been covering BioCryst Pharmaceuticals stock. The most successful analyst is Liisa Bayko.